VTA-27

VTA-27 is a preclinical small-molecule therapeutic candidate from VasThera being developed for Alzheimer's disease. Public company materials describe it as a blood-brain-barrier-penetrant peroxiredoxin mimetic intended to correct abnormal redox signaling associated with peroxiredoxin dysfunction in the brains of patients with Alzheimer's disease. VasThera has stated that preclinical studies showed reduction of astrocyte activation and neuroprotection with associated cognitive recovery signals, positioning VTA-27 as a potential disease-modifying neurodegeneration program rather than a symptomatic agent. Independent drug-database listings additionally characterize it as a TAU-directed anti-TAU small molecule, but the precise validated molecular target and binding pharmacology have not been clearly disclosed in primary public technical detail.